Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM

Area of Science:

• Neuro-oncology
• Cancer Biology
• Molecular Oncology

Background:

• Epidermal growth factor receptor (EGFR) gene amplification is common in glioblastoma (GBM).
• Despite EGFR amplification, therapies targeting this pathway have shown limited clinical success.
• EGFR inhibition can paradoxically promote tumor cell invasion and alter cellular stress responses.

Purpose of the Study:

• To investigate the effects of EGFR inhibition on GBM invasion and oxidative stress.
• To identify biomarkers associated with increased invasion and resistance to EGFR inhibitors.
• To explore aldehyde dehydrogenase (ALDH) as a potential therapeutic target in GBM.

Main Methods:

• Utilized human GBM tumors, patient-derived xenografts (PDX), and a murine GBM model.
• Assessed tumor cell invasion, oxidative stress markers (lipid peroxidation), and aldehyde dehydrogenase (ALDH) activity.
• Analyzed ALDH1A1 protein expression in GBM tissues before and after EGFR inhibitor therapy.
• Compared the sensitivity of ALDH1A1-high and ALDH1A1-low GBM clones to EGFR inhibition.

Main Results:

• EGFR inhibition increased GBM cell invasion and induced oxidative stress, including lipid peroxidation.
• A subpopulation of GBM cells with elevated aldehyde dehydrogenase (ALDH) levels was identified within invasive cell populations.
• ALDH1A1 expression was detected in 69% of newly diagnosed GBM cases and increased after EGFR inhibitor therapy.
• ALDH1A1-high GBM clones exhibited greater resistance to EGFR inhibition compared to ALDH1A1-low clones.

Conclusions:

• ALDH levels serve as a biomarker for GBM cells with high invasive potential, altered oxidative stress, and resistance to EGFR inhibition.
• Targeting ALDH may represent a novel therapeutic strategy to reduce GBM invasion.
• Understanding the role of ALDH in GBM progression is crucial for developing more effective treatments.